Patents based on PS Targeting (was messaged about me forgetting Salk Institute so will include / build a list of all Biotechs that have PS Targeting interest....)
1) Salk Institute / Kolltan Inventors: Greg E. Lemke, Lawrence C. Fritz, Benedikt VOLLRATH, Carla V. Rothlin
4) Institut National De La Sante Et De La Recherche Medicale (Inserm) Inventors: Ali Amara, Laurent Meertens
Publication date Aug 29, 2013 Filing date Feb 20, 2013 Priority date Feb 21, 2012
Edit: Adding Dart Neuroscience (Cayman) LTD.
5) Dart NeuroScience (Cayman) LTD.
Type: Application Filed: November 3, 2015 Publication date: November 23, 2017 Applicant: Dart Neuroscience (Cayman) Ltd. Inventors: Jillian Basinger, Brett Bookser, Mi Chen, Andrew Hudson, James Na, Joel Renick, Vincent Santora Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation Patent number: 9795591
Original Assignee The Board Of Trustees Of The Leland Stanford Junior University, Dana-Farber Cancer Institute, Inc., Children's Hospital Corporation, Less «
****************** 1 ********************
Quote: Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
Publication number US20170129947 A1 Publication type Application Application number US 15/270,813
Publication date 11 May 2017 Filing date 20 Sep 2016 Priority date 25 Jul 2012
Also published as CA2879542A1, EP2877211A1, EP2877211A4, EP3184121A2, US20150164800, WO2014018535A1, Less «
Inventors: Greg E. Lemke, Lawrence C. Fritz, Benedikt VOLLRATH, Carla V. Rothlin
Original Assignee: Salk Institute For Biological Studies, Kolltan Pharmaceuticals, Inc.
US 20170129947 A1 Abstract The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.
Quote: Read the post chain, especially the one before this post AND after you read it SLOWLY, then read this specific post below SLOWLY and finally, let it all sink in that Greg Lemke is coming in house to UTSWM with Dr. Rolf Brekken as host! Something big is being set up here ... http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117271035
This is about showing some background and ties to Carla Vanina Rothlin <> Greg Lemke, because Kolltan buys out the IP patent rights of Xertrios/Greg Lemke..etc and if you have been following these posts along you should know this but just for a refresher below and if you are just joining this gets interesting because Greg Lemke is welcomed into UTSWM next month with Dr. Rolf Brekken as host.
Quote: Gla domains as targeting agents US 9694048 B2
Abstract The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
Publication number US9694048 B2 Publication type Grant Application number US 14/773,068 PCT number PCT/US2014/026237
Publication date Jul 4, 2017 Filing date Mar 13, 2014 Priority date Mar 15, 2013
Also published as CA2905972A1, CA2905986A1, CN105008397A, CN105164152A, EP2970429A1, EP2970429A4, EP2970442A1, EP2970442A4, US20160008482, US20160106806, WO2014151535A1, WO2014151683A1, WO2014151683A8, Less «
Quote: Title: TUMOR IMMUNITY Document Type and Number: United States Patent Application 20170224793 Kind Code: A1
Abstract: Disclosed herein are materials and methods for treating cancer. In particular, compositions for stimulating tumor immunity through modulation of MFG-E8 are provided.
Quote: Tam receptors as virus entry cofactors WO 2013124324 A1 Abstract The present invention concerns the use of an inhibitor of an interaction between phosphatidylserine and a TAM receptor for preventing or treating a virus entry cofactors, in particular phosphatidylserine harboring virus infection such as flavivirus infection.
The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry
Laurent Meertens · Xavier Carnec · Manuel Perera Lecoin · Rasika Ramdasi · Ali Amara
Abstract: Dengue viruses (DVs) are responsible for the most medically relevant arboviral diseases. However, the molecular interactions mediating DV entry are poorly understood. We determined that TIM and TAM proteins, two receptor families that mediate the phosphatidylserine (PtdSer)-dependent phagocytic removal of apoptotic cells, serve as DV entry factors. Cells poorly susceptible to DV are robustly infected after ectopic expression of TIM or TAM receptors. Conversely, DV infection of susceptible... https://www.researchgate.net/scientific-contributions/2001916760_Laurent_Meertens
Original Assignee The Board Of Trustees Of The Leland Stanford Junior University, Dana-Farber Cancer Institute, Inc., Children's Hospital Corporation, Less «
Modulation of TIM receptor activity in combination with cytoreductive therapy US 8709412 B2 ABSTRACT A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with in the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1. ... ... ... Because TIM receptors can be activated by binding to phosphatidylserine, a phospholipid that is exposed in irradiated tumor tissues, IT with TIM receptors may demonstrate greater specificity (and fewer ‘off target’ autoimmune side effects) than other IT agents currently under development, and the functional interaction between TIM-1 and PS in the tumor immune microenvironment provides a unique method for focusing immune activation to the irradiated tumor.
The TIM-1 gene and protein have several known polymorphisms that influence the function of the TIM-1 in immune responses. These genetic variations are most common in the mucin domain that is involved with TIM-1 adhesion to extracellular molecules and plays an important role in T helper cell function. Mice with functional deletions in exon 4 of TIM-1 develop less robust helper T cell responses. In human populations a polymorphism involving exon 4 encodes a longer form of the mucin chain, and this polymorphism impacts immune function. This polymorphism in TIM-1 has been linked to susceptibility to asthma and autoimmunity. Polymorphisms determining the length of the mucin domain may be analyzed prior to treatment involving stimulation of a TIM receptor.
Tumors of interest for treatment with the methods of the invention include solid tumors, e.g. carcinomas, gliomas, melanomas, sarcomas, and the like. Breast cancer is of particular interest. Carcinomas include the a variety of adenocarcinomas, for example in prostate, lung, etc.; adernocartical carcinoma; hepatocellular carcinoma; renal cell carcinoma, ovarian carcinoma, carcinoma in situ, ductal carcinoma, carcinoma of the breast, basal cell carcinoma; squamous cell carcinoma; transitional cell carcinoma; colon carcinoma; nasopharyngeal carcinoma; multilocular cystic renal cell carcinoma; oat cell carcinoma, large cell lung carcinoma; small cell lung carcinoma; etc. Carcinomas may be found in prostrate, pancreas, colon, brain (usually as secondary metastases), lung, breast, skin, etc. Including in the designation of soft tissue tumors are neoplasias derived from fibroblasts, myofibroblasts, histiocytes, vascular cells/endothelial cells and nerve sheath cells. Tumors of connective tissue include sarcomas; histiocytomas; fibromas; skeletal chondrosarcoma; extraskeletal myxoid chondrosarcoma; clear cell sarcoma; fibrosarcomas, etc. .... .... .... http://www.google.com.gi/patents/US8709412
